Related Experiment Videos
A search for unknown blood-borne oncogenic viruses
International Journal of Cancer
|August 1, 1994
Summary
Infants receiving blood transfusions in early life were studied for cancer risks. This large cohort showed no significant increase in overall neoplastic disease or mortality, suggesting blood transfusions were not linked to excess cancer later in life.
Area of Science:
- Oncology
- Pediatrics
- Epidemiology
Background:
- Blood transfusions in infancy, particularly for hemolytic disease of the newborn, may pose risks of oncogenic virus transmission.
- Assessing long-term neoplastic disease and mortality in transfused infants is crucial for understanding transfusion safety.
Purpose of the Study:
- To investigate if infants transfused in utero or neonatally experienced increased cancer incidence or non-neoplastic mortality into adulthood.
- To evaluate the long-term health outcomes, specifically cancer risk, associated with early-life blood transfusions.
Main Methods:
- A cohort of 12,690 infants transfused between 1942 and 1970 was identified.
- Follow-up was conducted via National Health Service (NHS) records until 1992 to track mortality and cancer incidence.
- Observed rates were compared against expected national rates.
Main Results:
- No significant excess of overall neoplastic disease or non-neoplastic mortality was observed in the cohort.
- Childhood leukemia incidence was not elevated.
- A non-statistically significant doubling of non-Hodgkin's lymphoma incidence was noted between ages 15 and 49.
Conclusions:
- Early-life blood transfusions do not appear to confer a significant excess risk of neoplastic disease or mortality in adulthood.
- While a trend for non-Hodgkin's lymphoma was observed, it did not reach statistical significance, warranting further investigation if possible.